[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO]

Urologe A. 2017 Oct;56(10):1331-1332. doi: 10.1007/s00120-017-0480-7.
[Article in German]
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / pathology
  • Double-Blind Method
  • Humans
  • Muscle, Smooth / pathology*
  • Neoplasm Invasiveness
  • Neoplasm Metastasis / drug therapy*
  • Neoplasm Metastasis / pathology
  • Nivolumab / therapeutic use*
  • Treatment Outcome
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology*
  • Urologic Neoplasms / drug therapy*
  • Urologic Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Nivolumab